Drug intelligence / Profile preview

YR-D76

Development stage: Preclinical
Lead developer: Sichuan Enray Pharmaceutical Sciences
Modality: Small Molecules

Overview

YR-D76 is a preclinical small molecule dihydroorotate dehydrogenase (DHODH) inhibitor being developed by Sichuan Enray Pharmaceutical Sciences. It targets the coenzyme Q (CoQ) binding domain of the mitochondrial DHODH enzyme. By interfering with the ubiquinone (CoQ) reduction process, YR-D76 disrupts the mitochondrial ferroptosis defense pathway, inducing a lipid peroxidation storm that leads to ferroptotic cell death. Preclinical studies have demonstrated that YR-D76 has significant antitumor efficacy against refractory solid tumors, including pancreatic cancer.

Targets

DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)

Beyond the preview

Go deeper on YR-D76.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YR-D76.